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Abstract 1!
Nucleoside reverse transcriptase inhibitors (NRTIs) were the first drugs used to treat human 2!
immunodeficiency virus (HIV) the cause of acquired immunodeficiency syndrome. Development 3!
of severe mitochondrial toxicity has been well documented in patients infected with HIV and 4!
administered NRTIs. In vitro biochemical experiments have demonstrated that the replicative 5!
mitochondrial DNA (mtDNA) polymerase gamma, Polg, is a sensitive target for inhibition by 6!
metabolically active forms of NRTIs, nucleotide reverse transcriptase inhibitors (NtRTIs). Once 7!
incorporated into newly synthesized daughter strands NtRTIs block further DNA polymerization 8!
reactions. Human cell culture and animal studies have demonstrated that cell lines and mice 9!
exposed to NRTIs display mtDNA depletion. Further complicating NRTI off-target effects on 10!
mtDNA maintenance, two additional DNA polymerases, Pol beta and PrimPol, were recently 11!
reported to localize to mitochondria as well as the nucleus. Similar to Polg, in vitro work has 12!
demonstrated both Pol beta and PrimPol incorporate NtRTIs into nascent DNA. Cell culture and 13!
biochemical experiments have also demonstrated that antiviral ribonucleoside drugs developed to 14!
treat hepatitis C infection act as off-target substrates for POLRMT, the mitochondrial RNA 15!
polymerase and primase. Accompanying the above-mentioned topics, this review examines: 1) 16!
mtDNA maintenance in human health and disease, 2) reports of DNA polymerases theta and zeta 17!
(Rev3) localizing to mitochondria, and 3) additional drugs with off-target effects on 18!
mitochondrial function. Lastly, mtDNA damage may induce cell death; therefore, the possibility 19!
of utilizing compounds that disrupt mtDNA maintenance to kill cancer cells is discussed.  20!
 21!22!
! 3!
The origin of mitochondria and off-target effects of antibiotics  1!
 Mitochondria are best known for their role in generating energy by oxidative 2!
phosphorylation (OXPHOS), the process of coupling substrate oxidation to the production of the 3!
energy-rich molecule adenosine triphosphate (ATP). In addition to generating the bulk of the 4!
cell's energy supply mitochondria are important sites of calcium homeostasis, nucleotide and 5!
amino acid metabolism and biosynthesis of heme, iron-sulfur clusters, and ubiquinone. 6!
Mitochondria are eukaryotic organelles that share bacterial features such as a double-membrane 7!
structure and a circular multi-copied genome or mitochondrial DNA (mtDNA). The 8!
endosymbiotic theory hypothesizes mitochondria descended from an ancient alpha (α)-9!
proteobacteria that developed a symbiotic relationship with an ancient nucleated cell (1). Support 10!
for the endosymbiotic hypothesis comes from striking similarities revealed between the 11!
mitochondrial and the Rickettsia prowazekii genomes (2). Over time mitochondria lost most of 12!
their proto-bacterial genome to the nucleus. One thousand one hundred and forty-five nuclear-13!
encoded mitochondrial gene products must be imported into mitochondria following translation 14!
on cytoplasmic ribosomes and estimates place the total mitochondrial proteome at ~1500 gene 15!
products (3, 4). Currently, there are ~170 known mitochondrial disease genes associated with 16!
~500 clinical phenotypes suggesting that most medical specialists could see patients with 17!
mitochondrial disease (5, 6). The α-proteobacterial endosymbiont origin of mitochondria is 18!
supported by observations that certain antibiotics have off-target effects on mitochondrial 19!
ribosomes. Similar to bacterial translation, mitochondrial translation is initiated with an N-20!
formylmethionine and mitochondrial but not cytoplasmic translation is sensitive to bacterial 21!
antibiotics such as chloramphenicol (CAP) and aminoglycosides (7-9). Additionally, 22!
mitochondrial ribosomes are resistant to inhibitors of eukaryotic translation such as emetine and 23!
! 4!
cycloheximide (8).  1!
Mitochondrial disorders and the importance of mtDNA maintenance in human health 2!
 The haploid human nuclear genome consists of ~3 billion base pairs (bp) of DNA and 3!
contains ~20,000 protein-coding genes and ~23,000 non-coding genes. Examples of non-coding 4!
genes include transfer RNA (tRNA), ribosomal RNA (rRNA), micro RNA (miRNA), 5!
miscellaneous RNA (miscRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), 6!
small cytoplasmic RNA (scRNA), and long non-coding RNA (lncRNA). In comparison, the 7!
mitochondrial genome harbors only 13 genes for polypeptides, 2 genes for rRNA, and 22 genes 8!
for tRNA on ~16,600 bp and mutations associated with maternally-inherited mitochondrial 9!
disorders have been identified in all 37 open reading frames. Similar to practically all 10!
prokaryotic genes, human mtDNA genes lack introns. The 13 polypeptide-encoded genes code 11!
for subunits of the mitochondrial inner membrane (MIM) OXPHOS machinery. While the size 12!
and coding capacity of mtDNA is much less than the nuclear genome our maternally inherited 13!
genome is critical to cellular viability as exemplified by the numerous disease mutations 14!
associated with it and by observations that knocking out mtDNA maintenance genes results in 15!
embryonic lethality in various mouse models (10). Currently, greater than 660 mtDNA mutations 16!
are associated with disease phenotypes (www.mitomap.org). The most common 17!
encephalopathies caused by mtDNA point mutations include Leigh Syndrome, Leber Hereditary 18!
Optic Neuropathy, MERRF (myoclonic epilepsy with ragged red fibers), MIDD (maternally 19!
inherited diabetes and deafness), MELAS (mitochondrial encephalomyopathy, lactic acidosis, 20!
and stroke-like episodes), nonsyndromic hearing loss, and NARP (neuropathy, ataxia, retinitis 21!
pigmentosa) (11). Maintenance of the mitochondrial genome is also required to avoid apoptosis 22!
induced by mtDNA damage (12, 13). 23!
! 5!
 Molecules of mtDNA associate with various DNA-binding proteins on the matrix-side of 1!
the MIM and form protein-mtDNA structures known as nucleoids (14-17). Utilizing live-cell 2!
fluorescence microscopy or immunocytochemistry, nucleoids can be visualized as foci or puncta. 3!
Furthermore, a single cell can contain several thousand copies of mtDNA which are distributed 4!
within hundreds of individual mitochondria or throughout an elaborate mitochondrial reticular 5!
network (17-20). Localization of mtDNA at the MIM is likely important to coordinate mtDNA 6!
replication and transcription with mitochondrial translation, cytoplasmic translation, and 7!
mitochondrial protein import and assembly (18, 21). Nuclear-encoded mitochondrial 8!
transcription machinery is imported into the organelle to transcribe mtDNA genes. Nuclear-9!
encoded mitochondrial ribosomal subunits assemble with mtDNA-encoded rRNAs following 10!
protein import to form the translation machinery necessary to synthesize the 13 mtDNA-encoded 11!
polypeptides. Therefore, the MIM OXPHOS energy-generating process is strictly dependent on 12!
mtDNA maintenance and pharmacological blocks to mitochondrial genome replication would be 13!
devastating to this energy-generating process.  14!
Mitochondrial reactive oxygen species (ROS) and base excision repair (BER) 15!
 Aberrant electron leakage from the OXPHOS machinery to molecular oxygen (O2) can 16!
generate reactive oxygen species (ROS) which, if not detoxified, cause damage to intracellular 17!
molecules such as DNA, RNA, lipids, and proteins (22). The close proximity of mtDNA-18!
containing nucleoids to the OXPHOS machinery generating ROS has been suggested to inflict 19!
more damage on the mitochondrial genome than on the nuclear genome (12). ROS-induced DNA 20!
damage includes a large quantity of mutagenic oxidized bases and the mutation rate of human 21!
mtDNA has been estimated to be 20 to 100-fold higher relative to nuclear DNA. Nuclear-22!
encoded base excision repair (BER) machinery is imported into the mitochondrion to assist with 23!
! 6!
mending abnormal and oxidized base lesions. During mitochondrial short-patch BER, an 1!
oxidized base may first be excised by a monofunctional DNA glycosylase such as UNG1 or 2!
MUTYH, Figure 1 A. DNA glycosylase cleaves the damaged base N-glycosidic bond generating 3!
an abasic or apurinic/apyrimidinic (AP) site then this site is cleaved by an AP endonuclease to 4!
generate a 3'-OH and nonligatable 5'-deoxyribose phosphate (dRP) moiety. Next, the catalytic 5!
subunit of the replicative mitochondrial 5'-3' DNA polymerase gamma (Polγ) fills in the gap via 6!
its DNA polymerase activity and removes the dRP group via its 5'-deoxyribose phosphate (dRP) 7!
lyase activity leaving a 5'-phosphate. Lastly, DNA ligase III seals the nick and the damage is 8!
repaired (23). Alternatively, a bifunctional DNA glycosylase harboring an intrinsic lyase activity 9!
can cleave the N-glycosidic bond and incise the AP site; however, the ends generated by the 10!
incision are nonligatable and must be processed by either AP endonuclease or polynucleotide 11!
kinase 3'-phosphatase then Polγ can fill the gap and ligase can seal the nick (24, 25). Figure 1 A 12!
is a simplified cartoon of short-patch BER. Details regarding mitochondrial short-patch and 13!
long-patch BER pathways have been thoroughly reviewed (25-27).  14!
Polγ  and the replisome 15!
 Human Polγ is the replicative mitochondrial DNA polymerase that harbors 3'-5' 16!
exonucleolytic proofreading activity and participates in mtDNA repair (28). Polγ is a 17!
heterotrimer consisting of one 140-kDa catalytic subunit, p140 encoded by the nuclear POLG 18!
gene, and a 110-kDa homodimeric processivity subunit, p55 encoded by the nuclear POLG2 19!
gene. MtDNA disorders can be caused by genetic defects in nuclear genes, and a class of genes 20!
specifically linked to instability of mtDNA has emerged over the last 16 years which includes 21!
POLG and POLG2, Table 1 (28). Nuclear mitochondrial disease genes are associated with a 22!
! 7!
complex spectrum of early onset and late onset type phenotypes. One subclass of disorders, 1!
mtDNA depletion syndromes, may arise due to defects in genes encoding mtDNA replication 2!
machinery (ex. POLG, Alpers-Huttenlocher syndrome) or enzymes required for nucleotide 3!
synthesis (ex. TK2). MtDNA depletion syndromes in of themselves are variable and clinical 4!
manifestations may include myopathy, encephalomyopathy, neurogastrointestinal, or 5!
hepatocerebral phenotypes (29). In addition to the 5’-3’ DNA polymerase, 3'-5' exonuclease, and 6!
5’ dRP lyase activities mentioned above the p140 catalytic subunit harbors reverse transcriptase 7!
(RT) activity (30-32). The RT activity or RNA-dependent DNA polymerase activity is similar to 8!
viral enzymes such as human immunodeficiency virus RT (HIV-RT). Unfortunately, as will be 9!
discussed below, biochemical experiments have demonstrated that Polγ is sensitive to inhibition 10!
by metabolically active forms of anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) 11!
known as nucleotide reverse transcriptase inhibitors (NtRTIs). Treatment of HIV-infected 12!
patients with NRTIs is accompanied by loss of mitochondrial function and NRTI toxicity mimics 13!
mitochondrial genetic diseases and induces similar symptoms such as mtDNA depletion (31). 14!
One explanation as to why Polγ harbors RT activity may be to replicate past ribonucleotides 15!
(ribonucleoside monophosphates) that are evenly distributed between the two strands of mtDNA 16!
(32, 33). The homodimeric Polγ p55 subunit imparts high processivity onto the holoenzyme by 17!
increasing the binding affinity to DNA (17, 34). Processivity is a measurement of the extent of 18!
Polγ DNA synthesis during a primer-template binding event. Polγ functions in conjunction with 19!
several replisome components including:!1) topoisomerase, 2) mitochondrial single-stranded 20!
DNA binding protein (mtSSB), 3) Twinkle mtDNA helicase, 4) RNaseH1, 5) mitochondrial 21!
RNA polymerase (POLRMT), and 6) mitochondrial DNA ligase III, Figure 1 B. Additional 22!
factors critical for mitochondrial genome maintenance include: the multifunctional mitochondrial 23!
! 8!
transcription factor A (TFAM) with significant roles in mtDNA replication and packaging, the 1!
RecB-type mitochondrial genome maintenance 5’-3’ exonuclease 1 (MGME1), the RNA and 2!
DNA 5’ flap endonuclease (FEN1), and the helicase/nuclease, DNA2 (35-37). MGME1, FEN1, 3!
and DNA2 have all been implicated in mtDNA BER (26). Furthermore, DNA2 has been shown 4!
to stimulate Polγ activity and to co-localize with Twinkle in the mitochondrial nucleoid, which 5!
suggests an important role in the replisome (38). Some of the genes encoding components of the 6!
mtDNA replication machinery may have been acquired as part of a protomitochondrial genome, 7!
in the form of integrated phage genes from a T-odd lineage, which were then transferred to the 8!
eukaryotic nucleus (39). This hypothesis is based on the shared conservation of primary protein 9!
amino acid sequences of T-odd bacteriophages with mitochondrial Polγ, POLRMT, and Twinkle 10!
helicase.  11!
 In agreement with the requirement for mtDNA replication re-initiation between 12!
embryonic day (E)6 and 7.5 (40), p140 in animal cells was shown to be essential using POLG 13!
knockout (KO) mice. The POLG KO results revealed embryonic lethality at E7.5–8.5 with 14!
subsequent depletion of mtDNA (41). Comparatively, several studies have illustrated the 15!
essential role of p55 in mtDNA replication: (i) two separate null mutations in the Drosophila 16!
melanogaster POLG2 gene lead to lethality in the early pupal stage of fly development (42), (ii) 17!
homozygous POLG2 KO mice are embryonic lethal at E8–8.5 (43) and (iii) in a porcine oocyte 18!
knockdown model, oocyte maturation requires POLG2 (44). Mouse RNaseH1-/- embryos are null 19!
at E8.5 and have decreased mtDNA content leading to apoptotic cell death (45). A mouse model 20!
of Twinkle deficiency has been generated by transgenic expression of a Twinkle cDNA with an 21!
autosomal dominant mutation found in patients (46, 47). These mice developed progressive 22!
respiratory chain deficiency at 1 year of age in cerebellar Purkinje cells, hippocampal neurons, 23!
! 9!
and skeletal muscle. The affected cells accumulated multiple mtDNA deletions. These ‘Deletor’ 1!
mice recapitulate many of the symptoms associated with PEO and represent a useful research 2!
model.  3!
Newly identified human DNA polymerases localizing to mitochondria - Pols β , θ , 4!
ζ  and PrimPol 5!
 Prior to 2013 human Polγ was the 6!
only polymerase out of the 17 known cellular DNA polymerases demonstrated to localize to 7!
human cell mitochondria; however, mounting evidence suggests it is not the only one. Recently, 8!
DNA polymerase beta (Polβ) was detected in mitochondrial extracts prepared from human 9!
embryonic kidney cells (HEK-293T) and from various tissues obtained from mice (48). Analysis 10!
of mouse tissue extracts revealed Polβ in brain and kidney mitochondria while none was 11!
detectable in heart, liver, or muscle. As a key member of the nuclear BER machinery Polβ 12!
provides the majority of the required 5'-dRP lyase activity in the nucleus; therefore, Polβ may 13!
participate in mitochondrial BER. In a short-patch BER scenario, following the actions of a 14!
monofunctional DNA glycosylase and an AP endonuclease Polβ could insert a nucleotide onto 15!
the 3'-OH then remove the 5'-dRP group using its dRP lyase activity followed by the nick sealing 16!
action of DNA ligase (Figure 1 A). As mentioned above mitochondrial ribosomes are sensitive to 17!
CAP (CAPS). MtDNA can develop resistance to CAP (CAPR) through mutation of the mtDNA 18!
16S rRNA gene changing the specificity of CAP for the mitochondrial ribosome and inhibiting 19!
its binding (9, 48-50). In two HEK-293T Polβ KO cell lines very few CAPR cells could be 20!
isolated relative to the parental cell line when plated at high cell density. This finding suggests 21!
that Polβ may mediate mtDNA mutational events. Utilizing in vitro biochemistry Polβ was also 22!
! 10!
demonstrated to interact with the mitochondrial Twinkle helicase and this interaction facilitated 1!
Polβ strand displacement. Enhanced strand displacement suggests Polβ may participate in the 2!
mitochondrial long-patch BER pathway (48). As many Twinkle gene-disease mutations result in 3!
protein variants with partial helicase defects (51) it would be interesting to investigate strand 4!
displacement using recombinant Twinkle disease variants and Polβ to provide insight into 5!
possible mechanisms of Twinkle-related mitochondrial disease. Besides BER, other roles of Polβ 6!
in mtDNA maintenance remain to be elucidated. Polβ is not likely a replicative mtDNA 7!
polymerase as this enzyme lacks 3'-5' exonuclease proofreading activity, has low processivity, 8!
incorporating few nucleotides each time it binds a primer-template, and has a high error rate 9!
relative to the proofreading proficient Polγ (24). However, POLG-related disease mutations that 10!
abolish p140 activity and are associated with late age of onset may argue in favor of redundant 11!
DNA polymerase function(s) in human cell mitochondria (48). Polβ-/- mouse embryos survive 12!
the course of development but die immediately at the perinatal stage suggesting the cause of 13!
death is a neonatal respiratory defect (52).  14!
 The DNA primase and translesion DNA polymerase, PrimPol, has been identified in 15!
mitochondria isolated from HEK-293T cells (53). Translesion DNA polymerases are specialized 16!
enzymes that pass through DNA damage. However, PrimPol is likely only required for mtDNA 17!
repair and not for mtDNA replication, as PRIMPOL-/- KO mice are viable. Like Polβ PrimPol is 18!
localized to both the nucleus and the mitochondrion and lacks proofreading activity. Of note to 19!
human genetic disease, mutation of PRIMPOL is associated with the ocular disorder high myopia 20!
(54, 55). DNA polymerase theta (Polθ) was recently identified in mitochondria isolated from 21!
human cells (56). Polθ is a proofreading-deficient and error-prone polymerase capable of 22!
! 11!
translesion DNA polymerization (57). In the nucleus, Polθ is implicated in double-strand DNA 1!
break repair, non-homologous end joining and maintenance of DNA replication timing. The 2!
translesion DNA polymerase zeta (Polζ) is composed of two subunits the catalytic subunit Rev3 3!
and the structural subunit Rev7. To date, no evidence for Rev7 localization to human cell 4!
mitochondria has been described but the Rev3 subunit has been reported to localize to the 5!
organelle and may play a role in protecting mtDNA from ultraviolet radiation-induced DNA 6!
damage (58). Compared to Polγ, Pols θ and ζ localize to both the nucleus and the mitochondrion, 7!
have low fidelity, lack proofreading activity and have only moderate processivity (24, 57, 59); 8!
therefore, their main roles are likely in assisting the core replisome in overcoming mtDNA 9!
damage. Polθ KO mice are viable whereas Polζ KO mice are embryonic lethal with a block in 10!
embryo development not beyond 8 to 8.5 days post coitus (60, 61). Details regarding the 11!
evidence supporting mitochondrial localization of the aforementioned human DNA polymerases 12!
have been reviewed (62).  13!
Nucleoside reverse transcriptase inhibitors, NRTIs 14!
 NRTIs were the first drugs used to treat HIV, the cause of acquired immunodeficiency 15!
syndrome (AIDS). NRTIs remain effective today for treating HIV when combined with other 16!
drugs. Highly active antiretroviral therapy (HAART) uses multiple drugs to act on different HIV 17!
life-cycle stages. For patients with HIV infection, HAART regimens include treatment with 18!
NRTIs in combination with non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease 19!
inhibitors, PIs (63). NNRTIs and NRTIs primarily block HIV genome replication by inhibiting 20!
the HIV-RT from transcribing the viral single-stranded RNA genome into DNA. FDA-approved 21!
NRTIs used to treat HIV infection include: ddC (zalcitabine), 3TC (Epivir®, lamivudine), AZT 22!
! 12!
(Retrovir®, zidovudine), ddI (Videx-EC®, didanosine), PMPA (Viread®, tenofovir DF), d4T 1!
(Zerit®, stavudine), ABC (Ziagen®, abacavir), and FTC (emtricitabine, Emtriva®), Table 2. 2!
NRTIs may be administered to patients in fixed-dose combinations: Combivir® (Retrovir + 3!
Epivir), Descovy® (tenofovir alafenamide + Emtriva), Epzicom® (Epivir + Ziagen), Trizivir® 4!
(Retrovir + Epivir + Ziagen), and Truvada® (Viread + Emtriva), 5!
https://www.hiv.va.gov/patient/treat/NRTIs.asp. The history of antiretroviral drugs and the 6!
currently used antiretroviral therapies have been reviewed (64). A discussion of what is currently 7!
known regarding NRTIs with off-target effects on mtDNA replication is discussed below.  8!
 Nucleoside analogs, including NRTIs, are taken up by cells then phosphorylated to active 9!
nucleotide analogs by intracellular kinases (65). Nucleoside kinases such as DCK, CMPK1, and 10!
nucleoside diphosphate kinases (NME) act on NRTIs like ddC and perform the first, second, and 11!
third phosphorylation steps respectively generating the active NtRTI in the cytoplasm ex. 12!
ddCppp, where ppp represent the triphosphate (66). NtRTIs can then be imported into 13!
mitochondria and could compete with native nucleotides at DNA polymerase active sites to 14!
inhibit mtDNA replication through chain termination and persistence in the mitochondrial 15!
genome. Unlike natural deoxyribonucleotide triphosphate substrates, and with the exception of 16!
FIAU, NtRTIs are chain terminators that lack the 3' hydroxyl group and therefore cannot be 17!
extended by a polymerase once incorporated into DNA. Therefore, if these analogs are not 18!
removed from DNA, replication will stall (Figure 1 B).  19!
Clinical evidence for NRTI disruption of mtDNA replication 20!
 In clinical trials drugs that showed promise in AIDS therapy, such as fluoro-21!
dideoxyadenosine (FDDA), or in the treatment of chronic hepatitis B infection, such as FIAU, 22!
! 13!
toxicity was reported affecting peripheral nerves, liver, skeletal and cardiac muscle (67). 1!
Toxicity to mitochondria was so severe that hepatic failure and death in some patients 2!
necessitated discontinuation of their use (68). One long-term AZT use study of HIV-positive 3!
patients concluded that AZT treatment caused toxic mitochondrial myopathy (69). In a follow-up 4!
study investigating mtDNA content in muscle biopsies, mitochondrial genome depletion was 5!
discovered in all HIV-positive patients who were treated with AZT and who displayed myopathy 6!
and ragged-red fibers in comparison to controls (70). Another study investigated HIV-positive 7!
patients who developed neuropathy 6 to 10 weeks after starting ddC and this investigation found 8!
mitochondrial alterations and significantly reduced mtDNA copy number in nerve biopsy 9!
specimens (71). These and other observations led to the Polγ dysfunction hypothesis. 10!
Hypothetically, poisoning of Polγ would lead to decreased mtDNA, increased mitochondrial 11!
stress due to compromised OXPHOS (as OXPHOS subunits are encoded by mtDNA), increased 12!
cellular energy depletion (due to diminished ATP pools), and acquired mitochondrial disease 13!
phenotypes (72). Key side effects of NRTIs are summarized in Table 2 and (72). Support for the 14!
Polγ dysfunction hypothesis comes from cell culture and biochemical work discussed below. 15!
Evidence for Polγ-mediated NRTI toxicity from biochemical studies  16!
 Polγ-mediated NRTI mitochondrial toxicity requires that analogs be metabolized to 17!
NtRTIs, imported into mitochondria then incorporated into mtDNA and persist there to block 18!
further genome replication events. Support for NRTI toxicity caused by inhibition of Polγ DNA 19!
polymerase activity comes from extensive biochemical evidence. Pre-steady and steady-state 20!
enzyme kinetic analyses have demonstrated that Polγ is able to incorporate various anti-retroviral 21!
NtRTIs (73-76). NtRTIs that have been tested in vitro for incorporation into nascent DNA by 22!
! 14!
Polγ include: ddCppp, ddTppp, d4Tppp, ddAppp (the active form of ddI), (+) & (−)3TCppp, 1!
PMPApp (PMPA triphosphate), AZTppp, CBVppp (the active form of ABC), and FIAUppp. 2!
These biochemical studies agree that Polγ incorporates NtRTIs during DNA replication; 3!
however, the efficiency of analog incorporation is variable among the NtRTIs that have been 4!
examined. Polγ incorporates ddCppp, ddAppp (ddI), and d4Tppp analogs most efficiently while 5!
3TCppp, PMPApp, AZTppp, and CBVppp (ABC) are modestly incorporated into DNA. Steady-6!
state and pre-steady-state kinetics have also demonstrated that FIAUppp is strongly incorporated 7!
by Polγ (73, 77). Mitochondrial toxicity, therefore, may be acquired due to a block in mtDNA 8!
replication if chain-terminating NtRTIs cannot be removed. Indeed, biochemical evidence has 9!
shown that Polγ does not efficiently proofread NtRTIs incorporated into DNA. Pre-steady-state 10!
measurements have demonstrated that a ddCp (ddC monophosphate) incorporated into the 3'-end 11!
of a DNA oligonucleotide annealed to a DNA template essentially cannot be removed by Polγ 12!
proofreading activity even after 12-hour incubations with the DNA duplex (73). The remaining 13!
NtRTIs analyzed for exonucleolytic removal had slow rates of excision and it has been estimated 14!
that the half-life of the reaction to remove (+)3TCp or (−)3TCp is ~1 minute (78). The rate of 15!
NtRTI excision could be detrimental in vivo by slowing the mtDNA replication machinery. If 16!
Polγ dissociates from mtDNA prior to cleaving an incorporated nucleotide analog then 17!
replication would be terminated. When PMPA-terminated DNA substrate was tested for excision 18!
in the presence of trap DNA, no Polγ exonuclease activity was detected (73). This finding 19!
suggests that NtRTI-containing duplex DNA is released from Polγ prior to NtRTI excision and 20!
perhaps a similar mechanism could happen in vivo with many copies of mtDNA. Similar 21!
findings of slow rates of NtRTI excision were observed utilizing steady-state analyses. 22!
Additionally, Polγ exonuclease activity was inhibited at in vivo concentrations of the AZTppp 23!
! 15!
phosphorylated intermediate AZT monophosphate, AZTp (74). Perhaps in vivo intracellular 1!
levels of AZTp allow for binding of the analog to the exonuclease active site and lower Polγ's 2!
fidelity by blocking proofreading.  3!
 In 2015 crystal structures of Polγ-DNA replication complexes separately bound to 4!
ddCppp or to the natural substrate dCTP were solved (79). Within the DNA polymerase active 5!
site the side chain of the p140 Y951 residue stacks with the incoming ddCppp nearly identically 6!
to the natural dCTP substrate. The ribose sugar moieties of both nucleotides are located 3.5 Å 7!
from the p140 Y951 hydroxyl group. In support of the p140 Y951 residue being the likely cause 8!
of ddCppp toxicity, a biochemical study demonstrated that mutation of Y951 to phenylalanine 9!
maintains DNA polymerase activity but renders p140 Y951F almost completely incapable of 10!
incorporating ddCppp, CBVppp, 3TCppp, and d4Tppp (80). The p140 Y951F had a 2400-fold 11!
increase in dCTP/ddCppp discrimination relative to wild-type p140. Therefore, the substitution 12!
of the smaller phenylalanine side chain in the p140 Y951F variant must influence the structure 13!
such that ddCppp is excluded from the DNA polymerase active site and not readily incorporated 14!
into DNA.  15!
 Variability in mtDNA depletion has been observed in HIV-positive patients treated with 16!
NRTIs and may result from a difference in treatment times or from genetic variations that have 17!
increased susceptibility to NRTIs or both. A homozygous mutation encoding p140 R964C was 18!
identified in a 34-year-old HIV-infected woman with a history of lactic acidosis induced by d4T 19!
treatment (81). Recombinant p140 R964C displays 14% polymerase activity relative to WT 20!
p140. Additionally, a patient-derived p140 R964C lymphoblastoid cell line (LCL) cultured with 21!
d4T displays mtDNA depletion relative to a WT LCL suggesting p140 R964C is associated with 22!
! 16!
severe lactic acidosis induced by NRTI use. A pre-steady state analysis of Polγ holoenzyme 1!
harboring the p140 R964C variant determined that the substitution caused a 33% reduction in 2!
dTTP incorporation efficiency and a 3-fold decrease in dTTP/d4Tppp discrimination relative to 3!
WT suggesting p140 R964C has a higher propensity to incorporate d4Tppp (82). The p140 R964 4!
residue is located in close proximity to the DNA polymerase active site. One explanation for the 5!
mechanism of increased d4Tppp incorporation is that the p140 R964C substitution modulates 6!
active site access increasing binding to d4Tppp. Also, a heterozygous mutation (C>T 2857/p140 7!
R953C) was identified in an HIV-infected patient undergoing antiretroviral therapy who 8!
displayed mitochondrial toxicity and mtDNA depletion (83). The recombinant R953C Polγ 9!
holoenzyme displayed an 8-fold weakened ability to bind to dCTP and a 4-fold decrease in its 10!
ability to discriminate between dCTP and (−)-3TCppp relative to WT. Molecular modeling 11!
revealed that a cysteine substitution at position 953 in p140 could abolish interactions between 12!
p140 side chain residues in the active site thereby reducing the binding of an incoming 13!
nucleotide. In another case-control study examining the relationship between p140 E1143D/G 14!
substitutions, lipodystrophy, and d4T treatment it was concluded that HIV-infected patients 15!
harboring an E1143D/G variant are 4-fold more likely to develop lipodystrophy and if treated 16!
with d4T the risk of developing lipodystrophy increased (84).  17!
Evidence for NRTI disruption of mtDNA replication from cell culture and animal studies 18!
 Support for intracellular NRTI mitochondria toxicity mediated by disruption of mtDNA 19!
replication comes from observations that primary and immortalized cell lines undergo mtDNA 20!
depletion upon exposure to various NRTIs. Table 3 lists examples of human cell lines exposed to 21!
various nucleoside analogs in tissue culture. In some reports, mtDNA depletion was so severe 22!
! 17!
cell lines became rho zero completely lacking mtDNA. These findings are similar to what has 1!
been reported with LA9 mouse cells exposed to ddC (85) and with treating human cell lines with 2!
the mtDNA replication inhibitor ethidium bromide, EtBr (86). Low concentrations of EtBr either 3!
partially or completely inhibit maintenance of the negatively supercoiled circular mitochondrial 4!
genome but not nuclear DNA (nDNA). EtBr binds better to negatively supercoiled substrates 5!
than to positively supercoiled ones and might enhances topoisomerase-mediated cleavage of 6!
negatively supercoiled DNA; therefore, EtBr may act as a topoisomerase topological poison (87). 7!
In agreement with Polγ biochemical analyses, treatment of human cell lines with several 8!
nucleoside analogs typically duplicate the finding that ddC causes the most severe inhibition of 9!
mtDNA replication as indicated by mtDNA depletion. In an animal study investigating AZT 10!
exposure by administering the drug in drinking water to rats, transmission electron microscopy 11!
revealed widespread mitochondrial alterations in the heart following 35 days of treatment with 1 12!
mg/ml AZT (88). In another four-month study investigating the treatment of BALB/C mice with 13!
ddI, d4T, AZT, or 3TC, and with the exception of liver tissue from mice treated with 3TC, 14!
mtDNA depletion was reported in liver, muscle, and cortical neurons. Also, cortical neurons 15!
isolated from mice treated with ddI, d4T, and 3TC were reported to harbor an increased level of 16!
mtDNA deletions (89).  17!
Other potential mechanisms of NRTI toxicity  18!
 Other mechanisms of NRTI toxicity include increased frequency of mtDNA mutations 19!
(perhaps from an altered Polγ function), enhanced oxidative stress, and competition with 20!
endogenous nucleotides for kinases required to phosphorylate and activate them thereby 21!
lowering the in vivo concentrations of nucleotides available to replicate mtDNA (90). The recent 22!
! 18!
discovery of other cellular DNA polymerases localizing to human mitochondria also has 1!
implications for NRTI toxicity as these enzymes may incorporate analogs. Purified Polβ is 2!
considerably sensitive to NtRTIs including d4Tppp and ddCppp (75, 91) and compared to Polγ is 3!
less selective for and can incorporate AZTppp, PMPApp, L-FTCppp, and L-3TCppp, Table 2 4!
and (76). In the nucleus Pols alpha (α), delta (δ), and epsilon (ε) harbor strong nucleotide 5!
selection mechanisms and are less likely to incorporate NtRTIs (92). Incorporation of NtRTIs by 6!
Polβ within the organelle would be complicated by 1) the sensitivity of analog incorporation by 7!
Polγ and 2) the lack of Polβ proofreading activity, which would likely contribute to NtRTI 8!
persistence within mtDNA. Figure 1 A and B highlight key steps in BER and mtDNA replication 9!
that could be negatively affected by NtRTIs. Finally, the mitochondrial localization of DNA 10!
repair polymerases with flexible active sites could allow for accommodation of nucleotide 11!
analogs and contribute to unwanted insertion of chain terminators. Pre-steady-state analyses of 12!
PrimPol NtRTI incorporation kinetics revealed effective incorporation of CBVppp, followed by 13!
ddCppp > ddAppp > AZTppp while d4Tppp, 3TCppp, PMPApp, and FTCppp were not readily 14!
incorporated. From this study, it was determined that CBVppp is actually a better substrate for 15!
PrimPol than for HIV-RT which may help to explain life-threatening sensitivity to this analog in 16!
some patients (93). 17!
Evidence for POLRMT-mediated AVRN toxicity from biochemical and cell culture studies  18!
 POLRMT directs polycistronic transcription from three promoters the heavy-strand 19!
promoter 1 (HSP1), the HSP2, and the light-strand promoter, LSP (94), Figure 1 C. The two 20!
mtDNA strands are named heavy (H) and light (L) based on the ability to separate them on 21!
alkaline cesium chloride buoyant density gradients (95). RNA polymerase enzymes known as 22!
! 19!
primases synthesize RNA primers required for initiation of DNA replication. Evidence 1!
supporting the role of human POLRMT as the mtDNA primase comes from the identification of 2!
primers located adjacent to nascent H-strands isolated from human KB cell mitochondria (96), 3!
from in vitro experiments demonstrating that POLRMT has primase activity (97), and from the 4!
observation that replicating mtDNA obtained from mouse embryonic fibroblasts, and lacking 5!
RNaseH1, retain unprocessed primers at origins of replication (98). The 5’-end of RNA primers 6!
that have been mapped to the LSP therefore likely serve to initiate synthesis of nascent H-strand 7!
mtDNA (96), Figure 1 B. Consequently, mtDNA replication is likely dependent on 8!
mitochondrial transcription.  9!
 Sofosbuvir is an antiviral uridine analog inhibitor of hepatitis C virus (HCV) RNA-10!
dependent RNA polymerase (HCV non-structural protein 5B, NS5B) currently approved for use 11!
to treat patients with HCV infections. A number of reports have described the potential use of 12!
other antiviral ribonucleosides (AVRNs) as anti-viral and anti-cancer agents; however, many of 13!
these AVRNs have had adverse toxic effects when administered to patients and did not pass 14!
clinical trials or gain FDA approval (99, 100). For example, the AVRN analog BMS-986094 15!
developed to treat HCV infection did not pass phase II development after nine patients became 16!
hospitalized and one died (93). Utilizing a POLRMT in vitro biochemical system to measure 17!
substrate utilization a panel of more than ten AVRN analogs were investigated that contained 18!
moieties found in past and lead anti-HCV non-obligate chain terminators (100). Non-obligate 19!
chain terminators are AVRNs containing a 3'-OH yet prevent viral RNA elongation. Except for 20!
one analog, all AVRN triphosphates (AVRNts) investigated were readily utilized by POLRMT 21!
as off-target substrates and five analogs were strong non-obligate chain terminators of POLRMT 22!
RNA elongation. Utilizing the human hepatoma cell line, Huh-7, the panel of AVRNs were 23!
! 20!
metabolized to active triphosphates, presumably by intracellular kinases, and the levels of the 1!
triphosphate forms varied from less than 0.15 µM to 3.5 mM. Cellular evidence for AVRNs 2!
being used as substrates by POLRMT was demonstrated using Huh-7 cells pre-treated for 24 3!
hours with EtBr to suppress mitochondrial transcription then cells were exposed to AVRNs for 1, 4!
2, and 3 days. Mitochondrial transcription was impaired in cells exposed to 2'-C-5!
methyladenosine, 6-methylpurine-riboside, and 4'-azidocytidine. This study demonstrated that 6!
toxic effects of AVRNs might result from inhibition of the mitochondrial transcription 7!
machinery and mtDNA gene expression (100). Due to the close coupling of mitochondrial 8!
transcription and mtDNA replication, prolonged exposure to AVRNs might also affect mtDNA 9!
maintenance, Figure 1 B and C.  10!
Other reports of drugs with off-target effects on mtDNA maintenance  11!
 Four human cellular topoisomerases localize to mitochondria: TOP1mt, TOP2α, TOP2β, 12!
and a TOP3α long isoform (101, 111). Tamoxifen a drug used to prevent breast cancer, tacrine a 13!
drug used to treat Alzheimer's disease, and a fluoroquinolone broad-spectrum antibiotic, have all 14!
been hypothesized to have off-target effects on mitochondrial topoisomerases (102-106). Mice 15!
separately treated for 28 days with tamoxifen and tacrine displayed mtDNA depletion and both 16!
of these drugs were demonstrated to inhibit in vitro topoisomerase-mediated plasmid DNA 17!
relaxation (103, 104). The fluoroquinolone ciprofloxacin, an inhibitor of bacterial type II 18!
topoisomerase DNA gyrase, was reported to induce double-strand mtDNA breaks when mouse 19!
L1210 cells were exposed to various concentrations of the drug (106). The pyrrole alkaloid 20!
lamellarin D and the chemotherapy drug doxorubicin have both been shown to poison 21!
mitochondrial and nuclear topoisomerases (101).  22!
 Menadione (vitamin K3, VK3) has been demonstrated to inhibit the growth of human 23!
! 21!
cancer cell lines derived from various tissues and induces an increase in ROS leading to 1!
apoptosis. In an in vitro biochemical assay VK3 selectively inhibited Polγ DNA polymerase and 2!
RT activities but did not inhibit the activity of other DNA polymerases tested including Pols 3!
α, β, δ, ε, eta (η), iota (ι), kappa (κ), and lambda (λ). The authors proposed that suppression of 4!
mtDNA replication and repair could trigger ROS production leading to apoptotic cell death 5!
(107). Although the neurotoxicant 1-methyl-4-phenylpyridinium ion (MPP+) does not directly 6!
inhibit the catalytic activity of Polγ, MPP+ was reported to cause mtDNA depletion by 7!
destabilizing the mtDNA displacement-loop, a mtDNA replication intermediate, thereby 8!
inhibiting mitochondrial genome replication (108). Acetaminophen (APAP or paracetamol) is a 9!
commonly used over the counter drug used for fever and pain relief. Mice treated with 300 10!
mg/kg of acetaminophen had mtDNA depletion as quantitated using a slot blot hybridization 11!
technique (109). The depletion is likely due to mtDNA stand breaks caused by the production of 12!
ROS, reactive nitrogen species (RNS), and other reactive metabolites followed by rapid 13!
degradation of damaged mtDNA by endogenous mitochondrial endonucleases (102). 14!
Troglitazone is an anti-inflammatory and anti-diabetic drug that was withdrawn from the market 15!
due to serious hepatotoxicity. Primary human hepatocytes exposed to troglitazone had increased 16!
mtDNA depletion, decreased ATP production, and decreased cellular viability (110). ROS and 17!
oxidative stress were hypothesized to be the source of mtDNA depletion causing mtDNA strand 18!
breaks and cytotoxicity and treatment with N-acetyl cysteine (NAC), a known ROS scavenger, 19!
reduced the troglitazone-induced cytotoxicity. Cisplatin is a platinum-based FDA-approved 20!
chemotherapeutic known to damage nDNA by forming inter-strand crosslinks. Patients treated 21!
with platinum-based compounds often display peripheral neuropathy, which may result from 22!
damage to dorsal root ganglion neuronal mtDNA (112). In vitro work has demonstrated cisplatin 23!
! 22!
or oxaliplatin block Polγ DNA synthesis. Furthermore, cisplatin has been demonstrated to inhibit 1!
rat neuronal mtDNA replication and mitochondrial transcription (112-114).  2!
Targeting mtDNA maintenance to kill cancer cells  3!
 Cancer cells display uninhibited DNA replication; therefore, DNA polymerases and DNA 4!
repair proteins have been exploited as therapeutic targets to combat certain types of cancer (115, 5!
116). NRTI-sensitive mitochondrial DNA polymerases afford a unique opportunity to target 6!
cancer cell mitochondria as certain cancers have an increased reliance on OXPHOS and nDNA 7!
polymerases are less sensitive to NRTI inhibition (66, 75). In a study comparing normal 8!
hematopoietic cells to a panel of 542 primary acute myeloid leukemia (AML) samples, it was 9!
recently discovered that 55% of the AML samples had increased mtDNA biosynthesis gene 10!
expression. Upregulated genes included POLG, POLG2, POLRMT, Twinkle, TFAM, SSBP1, 11!
DGUOK, TK2, nucleotide transporters (SLC25A33, SLC25A36, and SLC29A3) and nucleoside 12!
kinases (CMPK1 and NME1-NME2). When treated with ddC AML cells preferentially activated 13!
the analog and blocked mtDNA replication and OXPHOS in comparison to hematopoietic cells. 14!
Cytotoxicity was preferentially activated in NRTI-treated AML cells and an AML animal model 15!
treated with low doses of ddC (35 and 75 mg/kg/day over 11 days) resulted in decreased 16!
mtDNA, decreased mtDNA-encoded cytochrome oxidase subunit 2 (COX II), and induced tumor 17!
regression without apparent toxicity (66).  18!
 Targeting mtDNA maintenance has also been exploited to treat cancer cell lines with a 19!
mitochondrial-targeted cisplatin (117). Nucleotide excision repair (NER) machinery repairs 20!
cisplatin-nDNA adducts; however, mitochondria lack NER machinery to deal with this type of 21!
damage. Most cancer cells have an increased mitochondrial membrane potential relative to non-22!
cancer cells and triphenylphosphonium (TPP) cations are targeted to mitochondria due to their 23!
! 23!
size, lipophilic properties, and delocalized positive charge. An engineered TPP-tagged cisplatin, 1!
Platin-M, caused increased cytotoxicity relative to cisplatin only treatment in several cancer cell 2!
models: cisplatin-resistant A2780/CP70 ovarian cancer, prostate cancer PC3 (inherently resistant 3!
to cisplatin therapy), and SH-SY5Y neuroblastoma cells. Furthermore, encapsulating Platin-M 4!
into specialized nanoparticles enhanced cytotoxicity. SH-SY5Y cells treated with Platin-M and 5!
Platin-M encapsulated in nanoparticles were annexin V-positive and propidium iodide-negative, 6!
indicative of early apoptosis. Treatment with both Platin-M and Platin-M encapsulated in 7!
nanoparticles weakened mitochondrial citrate synthase activity and diminished bioenergetic 8!
parameters: spare respiratory capacity, coupling efficiency, and basal respiration. PC3 cells 9!
treated separately with cisplatin, Platin-M, and Platin-M encapsulated inside of nanoparticles 10!
were subjected to subcellular fractionation then platinum concentrations in various fractions 11!
were quantified. Cells treated with Platin-M and Platin-M encapsulated in nanoparticles, 12!
contained platinum-mtDNA adducts while cells treated with cisplatin contained mostly platinum-13!
nDNA adducts. These findings support that cisplatin is likely released from Platin-M within 14!
mitochondria then binds to mtDNA and inhibits replication.  15!
Conclusions 16!
 Evaluation of antibiotic and antiviral mitochondrial exposures using biochemistry and 17!
human cell line and animal models is an important consideration for determining drug toxicity 18!
because the complex mitochondrial network harbors multiple copies of OXPHOS complexes and 19!
mtDNA that may cause a slow response to these agents. Chronic exposures to drugs may result 20!
in long-term mtDNA and OXPHOS depletion. NRTIs may have tissue-specific toxicities such as 21!
skeletal- and cardio-myopathies, peripheral neuropathy, and others (Table 2 and (67)). Side 22!
effects may limit NRTI use in some individuals, cause organ failure and death in others or may 23!
! 24!
only result in minor discomfort (72). Gene variations (like those seen in POLG encoding p140 1!
R964C, R953C, and E1143D/G) may exacerbate mitochondrial disease-like phenotypes in HIV-2!
infected patients treated with NRTIs. Also, valproic acid has been demonstrated to induce liver 3!
failure in autosomal recessive POLG disease but may not be as toxic in autosomal dominant 4!
disease. However, due to the potential for valproic acid to cause death by liver toxicity experts 5!
recommend avoiding this drug (118). POLG is a highly polymorphic gene and the association 6!
between disease-causing and non-disease causing substitutions are often unclear and dependent 7!
on other complex factors. How other drugs or environmental factors interact with various genetic 8!
variant backgrounds (so-called ecogenetic single nucleotide variants, ESNVs) and contribute to 9!
mitochondrial disease manifestation is poorly understood (118, 119). Do ESNVs predispose 10!
individuals to mitochondrial dysfunction via pharmacological or environmental toxicants while 11!
individuals harboring other polymorphism remain resistant? ESNV-environment interaction is an 12!
important area for future mitochondrial disease and mtDNA maintenance research. Evidence 13!
suggests mitochondria are targets of environmental toxicants that disrupt mtDNA maintenance 14!
and chemical exposures may cause increased and decreased mtDNA copy number. At low doses, 15!
oxidative stress stimulates mtDNA replication but at high doses mtDNA depletion. Polycyclic 16!
aromatic hydrocarbons cause more damage to mtDNA than to nDNA and a compilation of 17!
studies comparing nDNA to mtDNA damage following chemical exposure has been reviewed 18!
(120).  19!
 Evidence suggests five DNA polymerases localize to human cell mitochondria: Polγ, 20!
Polβ, PrimPol, Polθ, and Pol ζ. In vitro biochemistry measuring substrate binding and 21!
incorporation lends strong support to Polγ, Polβ, and PrimPol being off-targets for nucleotide 22!
analogs (79, 91). Additionally, the Polθ carboxyl-terminal polymerase domain has been 23!
! 25!
crystallized in a translesion DNA synthesis mode inserting ddAppp opposite a template abasic 1!
site (121). Comparative investigations of mtDNA polymerase enzyme kinetics and determination 2!
of crystal structures with and without lesions will assist in our understanding of the spectrum of 3!
mtDNA polymerase toxicity. The overarching goal is that these structure-function studies will 4!
assist with designing novel antiviral analogs with higher specificity to viral polymerases and less 5!
mitochondrial off-target effects. In mice, mitochondrial Polβ was undetectable in heart, liver, and 6!
muscle but was present in organelles obtained from brain and kidney (48). Potential questions for 7!
future research include: 1) How are the other newly identified mtDNA polymerases distributed 8!
among human organs and tissues and do they associate with other components of the mtDNA 9!
repair or replication machinery? Knowledge of the distribution of mtDNA polymerases within 10!
human tissues may assist with the prediction of tissue-specific toxicant effects. 2) Could 11!
knowledge of mtDNA polymerases within different tissues be exploited to treat certain types of 12!
cancers with NRTIs? 3) What analogs and toxicants are incorporated by the newly identified 13!
mtDNA polymerases? And 4) Do ESNVs exist in any other genes of interest required for 14!
mtDNA maintenance? Current next-generation sequencing technologies and continued research 15!
utilizing in vitro biochemistry and model systems such as human cell lines and mice will be 16!
essential to answer these questions and will be necessary for future investigations of 17!
mitochondrial dysfunction and disease.  18!
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Figure 1. MtDNA maintenance and mitochondrial gene expression. A. Mitochondrial short-1!
patch base excision repair (BER) initiated with a monofunctional DNA glycosylase. The ROS 2!
lightning bolt represents reactive oxygen species-induced mtDNA damage generating an 3!
oxidized base lesion (star) that is subsequently removed and repaired by the BER machinery. 4!
Two blue circles represent the double-stranded circular mitochondrial genome. A region of the 5!
damaged mtDNA is shown below the circular genome to emphasize the BER pathway steps. AP 6!
site, apurinic/apyrimidinic site; AP endo, AP endonuclease; dRP, 5’-deoxyribose phosphate; 7!
Polγ/β the replicative mtDNA polymerase gamma or DNA polymerase beta; LigIII, 8!
mitochondrial DNA ligase III. The NtRTIs lightning bolt represents nucleotide reverse 9!
transcriptase inhibitors blocking Polγ or β. B. Key components of the mtDNA replication and 10!
repair machinery. The small purple line represents an RNA primer while the blue dashed line 11!
represents newly synthesized mtDNA. TOPO, topoisomerase; Twinkle, Twinkle mtDNA 12!
helicase; POLRMT, mitochondrial RNA polymerase and primase; RNaseH1, Ribonuclease H1; 13!
mtSSB, mitochondrial single-stranded DNA binding protein. DNA polymerase beta, theta, zeta, 14!
and the DNA primase and translesion DNA polymerase are represented by Pols β, θ, ζ, and 15!
PrimPol respectively. These polymerases likely assist Polγ with overcoming mtDNA damage. 16!
The AVRNts lightning bolt represents antiviral ribonucleotides blocking POLRMT activity. C. 17!
Polycistronic mitochondrial transcription. Mitochondrial transcription (TS) occurs from three 18!
promoters: 1) LSP, light-strand promoter, 2) HSP1, heavy-strand promoter 1, and 3) HSP2, 19!
heavy-strand promoter 2. Three purple dashed lines represent transcripts synthesized from the 20!
promoters. Although not visualized in the cartoon, mitochondrial TS initiation requires 21!
mitochondrial TS factor A (TFAM) and either of mitochondrial TS factors B1 or B2 (TFB1M or 22!
! 35!
TFB2M). It is generally accepted that TFB2M is the primary factor for TS initiation (122). 23!
Mitochondrial TS termination factor is represented by mTERF. 24!
Table 1. Nuclear genes identified in mitochondrial patients that affect mtDNA stabilitya 25!
 26!
Gene Disorderb Chromosomal 
locus 
Function 
 
MtDNA replication and repair 
POLG PEO / Alpers / ataxia 15q25 Polγ catalytic subunit 
POLG2 PEO 17q Polγ processivity subunit 
Twinkle PEO / ataxia 10q24 MtDNA helicase 
RNASEH1 PEO / ataxia  2p25 Mitochondrial and nuclear RNaseH1 (123) 
DNA2 PEO 10q21.3-22.1 Mitochondrial and nuclear helicase/nuclease (124) 
MGME1 PEO, mtDNA depletion 20p11.23 RecB type exonuclease 
TFAM Neonatal liver failure mtDNA depletion 10q21.1 
Mitochondrial transcription factor A 
(29) 
 
Maintaining dNTP pools 
ANT1 PEO 4q35 Adenine nucleotide translocator 
TP MNGIE 22q13.33 Thymidine phosphorylase 
DGUOK MtDNA depletion 2p13 Deoxyguanosine kinase 
TK2 MtDNA depletion 16q22-23.1 Mitochondrial thymidine kinase 
SUCLA2 MtDNA depletion 13q14.2 ATP-dependent Succinate-CoA ligase 
SUCLG1 MtDNA depletion 2p11.2 GTP-dependent Succinate CoA ligase 
RRM2B MtDNA depletion 8q23.1 p53-Ribonucleotide reductase, small subunit 
MPV17 MtDNA depletion and deletion  2p23.3 
Mitochondrial inner membrane 
protein 
ABAT MtDNA depletion 16p13.2 4-aminobutyrate aminotransferase (125) 
 
Mitochondrial homeostasis and dynamics 
OPA1 Dominant optic atrophy 3q29 Dynamin-related GTPase 
MFN2 Recessive optic atrophy 1p36.22 Mitofusin 2 (126) 
FBXL4 MtDNA depletion, Encephalopathy 6q16.1-16.3 Mitochondrial LLR F-Box protein 
aThe table is an updated version of Table 1 found in reference (28) and is reproduced with permission  27!
bPEO, progressive external ophthalmoplegia; MNGIE, mitochondrial neurogastrointestinal 28!
encephalomyopathy 29!
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Table 2. NRTIs with off-target effects on human DNA polymerases that localize to mitochondria  
  
! !
Drug  Target Potenti
al off-
targeta 
Mode of 
action 
Side effects/toxicity/other notes Experimental evidence for off-
target effect 
Reference 
ddC, 2',3'-
dideoxycytidine, 
zalcitabine, hivid 
HIV-
RT 
Polγ, 
PrimPol
, Polβ 
Deoxycytidi
ne analog, 
chain-
terminator 
Peripheral neuropathy, 
sensorineural deafness, 
hypertrophic cardiomyopathy; 
according to the FDA ddC is no 
longer marketed  
MtDNA depletion in various 
human cell lines; efficiently 
incorporated by Polγ and PrimPol, 
in vitro (Polγ 14-fold reduction in 
dCTP/ddCppp discrimination 
relative to PrimPol); 
Polβ incorporates and sensitive to 
ddCppp inhibition in vitro 
(67, 73-
75, 91, 93, 
127-131) 
ddI, 2',3'-
dideoxyinosine, 
didanosine, Videx-
EC® 
HIV-
RT 
Polγ, 
PrimPol
, Polθ? 
Deoxyadeno
sine analog, 
chain-
terminator 
Peripheral neuropathy, 
pancreatitis, hypertrophic 
cardiomyopathy, diabetes 
mellitus, hepatocellular failure, 
lactic acidosis; ddI is 
metabolized to ddAppp 
Aberrant cristae and decreased 
mtDNA copy number in human 
cell lines; ddAppp (active form of 
ddI) incorporated efficiently by 
Polγ and incorporated by PrimPol 
in vitro (Polγ 233-fold reduction in 
dATP/ddAppp discrimination 
relative to PrimPol) 
(67, 73, 
93, 121, 
127, 128, 
132) 
d4T, 2',3'-didehydro-
2',3'-
dideoxythymidine, 
stavudine, Zerit® 
HIV-
RT 
Polγ,  
Polβ 
Thymidine 
analog, 
chain-
terminator 
Peripheral neuropathy, 
pancreatitis, hepatocellular 
failure, lactic acidosis, 
lipodystrophy; no longer 
recommended for administration 
Aberrant cristae and decreased 
mtDNA copy number in human 
cell lines; incorporated efficiently 
by Polγ in vitro; Polβ incorporates 
and sensitive to d4Tppp inhibition 
in vitro 
(67, 72-
75, 127, 
128, 133) 
3TC, 2',3'-dideoxy-3'-
thiacytidine, 
lamivudine, Epivir® 
HIV-
RT 
Polγ,  
Polβ 
Zalcitabine/
cytosine 
analog (see 
above), 
chain-
terminator 
Peripheral neuropathy, lactic 
acidosis, hepatomegaly with 
steatosis 
Kinetic analysis with HeLa Polγ, 
modest inhibition of Polγ in vitro; 
Polβ has a 9-fold reduction in 
dCTP/L-3TCppp discrimination in 
comparison to Polγ in vitro 
(67, 72-
74, 76) 
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PMPA, (R)-9- (2-
phosphonylmethoxyp
ropyl)adenine, TFV, 
tenofovir 
HIV-
RT 
Polγ,  
Polβ 
Deoxyadeno
sine analog, 
chain-
terminator 
Mitochondrial nephrotoxicity, 
kidney dysfunction; 
Viread®/TDF is a prodrug of 
PMPA 
Modest inhibition of Polγ in vitro; 
Polβ has a 270-fold reduction in 
dATP/PMPApp discrimination in 
comparison to Polγ in vitro 
(72, 73, 
76) 
AZT, 3'-azido-2',3'-
dideoxythymidine, 
zidovudine, ZDV, 
Retrovir® 
HIV-
RT 
Polγ, 
PrimPol
, Polβ 
Thymidine 
analog, 
chain-
terminator, 
decreases 
levels of 
pyrimidines 
Myopathy including ragged red 
fibers, decreased muscle 
mtDNA, bone marrow 
suppression, hypertrophic 
cardiomyopathy, sideroblastic 
anemia, pancytopenia, 
hepatocellular failure, lactic 
acidosis 
Decreased mtDNA in cell culture, 
biochemical defects with Polγ in 
vitro; modestly incorporated by 
Polγ; Polβ has an ~3850-fold 
reduction in dTTP/AZTppp 
discrimination relative to Polγ and 
PrimPol has an ~60-fold reduction 
in dTTP/AZTppp discrimination 
relative to Polγ in vitro. 
(67, 73, 
74, 76, 93, 
134) 
CBV, (−)-cis-2-
amino-1,9-dihydro-9-
(4-hydroxymethyl)-2-
cyclopenten-1-yl)-
6H-purin-6-one, 
carbovir active form 
of abacavir, ABC, see 
below 
HIV-
RT 
Polγ, 
PrimPol 
Deoxyguano
sine analog, 
chain-
terminator 
See below Strongly incorporated by PrimPol 
in vitro and modest inhibition of 
Polγ in vitro 
(67, 73, 
74, 93) 
ABC, [(1S,4R)-4-[2-
amino-6-
(cyclopropylamino)-
9-purinyl]-1-
cyclopent-2-
enyl]methanol, 
abacavir, Ziagen® 
HIV-
RT 
Polγ, 
PrimPol 
Deoxyguano
sine analog, 
chain-
terminator 
Increased myocardial infarction 
and congestive heart failure; 
Note: following intracellular 
phosphorylation ABC 
monophosphate is converted to 
CBV monophosphate by 
cytosolic enzymes then to 
CBVppp by cellular kinases 
See CBV above (72, 93) 
FIAU, 1-(2-deoxy-2-
fluoro-β-D-
arabinofuranosyl)-5-
iodouracil, 
fialuridine, 
fluoroiodoarauridine  
Hepatit
is B, 
herpes 
virus 
DNA 
pols 
Polγ Uridine 
analog, not a 
chain 
terminator 
as it 
contains a 3' 
OH, but 
Severe lactic acidosis, liver 
failure, and steatosis, kidney 
failure, myopathy, peripheral 
neuropathy; discontinued use 
due to severe hepatotoxicity and 
death 
Inhibition of Polγ in vitro, 
cytotoxic to human Molt-4 cells, 
aberrant mitochondrial structures 
(67, 68, 
73, 75) 
! 38!
aThe Polθ carboxyl-terminal polymerase domain has been crystalized inserting ddAppp opposite a template abasic site (121) 
impairs 
DNA 
elongation 
at adenosine 
tracts (77) 
FTC, 5-fluoro-1-
[(2R,5S)-2-
(hydroxymethyl)-1,3-
oxathiolan-5-
yl]cytosine, RCV, 
emtricitabine, 
Emtriva®, coviracil, 
racivir 
HIV-
RT 
Polγ,  
Polβ 
Deoxycytidi
ne analog, 
chain 
termination 
 
Lactic acidosis, hepatomegaly 
with steatosis 
Polβ has a 100-fold reduction in 
dCTP/FTCppp discrimination in 
comparison to Polγ in vitro 
(72, 76) 
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Table 3. NRTIs that disrupt mtDNA maintenance in human cell lines 
 
Cell line Source of cell line Nucleoside Analog 
or agent studieda 
Effect on mtDNA maintenance Treatment 
time 
Ref. 
Molt-4  T lymphoblast AZT, d4T, FLT, 
935U83, FIAU, 
524W91, 3TC, ddC, 
ddI 
ddC and FLT, mtDNA depletion and cell death; 
d4T caused mtDNA depletion; FIAU did not 
alter ratio of mtDNA to nDNA but was 
cytotoxic; 524W91, AZT, 935U83 no detectable 
affect on mtDNA or cell growth 
5 days (FIAU 
and ddC), 6 
days (d4T), 
rest 7 days 
(75) 
HepG2 Hepatocellular 
carcinoma 
PMPA, 3TC, ABC, 
ddC, ddI, d4T, and 
AZT 
PMPA, 3TC, & ABC had no detectable effects 
on mtDNA levels; ddC > ddI > d4T > AZT 
depletion of mtDNA 
9 days (127) 
Primary SkMC Skeletal muscle cells PMPA, 3TC, ABC, 
ddC, ddI, d4T, and 
AZT 
PMPA, 3TC, ABC, AZT had no detectable 
effects on mtDNA levels; ddC > ddI > d4T 
depletion of mtDNA 
9, 18, and 21 
days 
(127) 
Primary RPTECs Renal proximal 
tubule epithelial cells 
PMPA, ddC, ddI, 
d4T, and AZT 
PMPA & AZT had no detectable effects on 
mtDNA levels; ddC > ddI > d4T depletion of 
mtDNA 
12 and 21 
days 
(127) 
Lymphocytes  Primary peripheral 
blood lymphocytes  
ddC, ddI, d4T, AZT ddI> ddC > d4T deplete mtDNA; AZT did not 
affect mtDNA but increased lactic acid 
production and reduced cell counts 
10 days (128) 
Lymphoblastoid 
cell line 
Blood lymphocytes 
transformed with the 
Epstein Barr Virus 
ddC MtDNA depletion down to 20% of untreated 
cells  
15 days (129) 
HCA2-htert Fibroblast cell line 
immortalized by 
over-expression of 
human telomerase 
ddC Extreme mtDNA depletion 8 days (130) 
KP hMSC Immortalized 
mesenchymal/stromal 
cell line 
EtBr, AZT, d4T MtDNA depletion EtBr > d4T > AZT 10 days (134) 
3a6 hMSC Immortalized 
mesenchymal/stromal 
cell line 
EtBr, AZT, d4T MtDNA depletion d4T > EtBr; AZT no 
detectable mtDNA depletion 
6 (d4T), 9 
(AZT), or 10 
(EtBr) days 
(134) 
HeLa Cervical cancer cells ddC MtDNA depletion  3 days (131) 
CEM Leukemia cell line ddC, d4T, ddI  MtDNA depletion, potencies in reducing cell 4 days  (132) 
! 40!
viability, mtDNA content and normal 
mitochondrial morphology were ddC > d4T > 
ddI !
aFLT, 3'-fluoro-3'-deoxythymidine; 935U83, 3'-fluoro-2',3'-dideoxy-5-chlorothymidine; 524W91, [(−) FTC], (−)-β-L-2',3'-dideoxy-5-fluoro-3'-
thiacytidine; EtBr, ethidium bromide  
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